- Home
- ORIC vs PLRX Comparison
ORIC vs PLRX Comparison
Compare ORIC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- PLRX
- Stock Information
- Founded
- ORIC 2014
- PLRX 2015
- Country
- ORIC United States
- PLRX United States
- Employees
- ORIC N/A
- PLRX N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- PLRX Health Care
- Exchange
- ORIC Nasdaq
- PLRX Nasdaq
- Market Cap
- ORIC 735.3M
- PLRX 680.3M
- IPO Year
- ORIC 2020
- PLRX 2020
- Fundamental
- Price
- ORIC $11.08
- PLRX $11.61
- Analyst Decision
- ORIC Strong Buy
- PLRX Strong Buy
- Analyst Count
- ORIC 9
- PLRX 7
- Target Price
- ORIC $18.75
- PLRX $40.50
- AVG Volume (30 Days)
- ORIC 825.1K
- PLRX 485.5K
- Earning Date
- ORIC 03-10-2025
- PLRX 02-26-2025
- Dividend Yield
- ORIC N/A
- PLRX N/A
- EPS Growth
- ORIC N/A
- PLRX N/A
- EPS
- ORIC N/A
- PLRX N/A
- Revenue
- ORIC N/A
- PLRX N/A
- Revenue This Year
- ORIC N/A
- PLRX N/A
- Revenue Next Year
- ORIC N/A
- PLRX N/A
- P/E Ratio
- ORIC N/A
- PLRX N/A
- Revenue Growth
- ORIC N/A
- PLRX N/A
- 52 Week Low
- ORIC $6.33
- PLRX $10.22
- 52 Week High
- ORIC $16.65
- PLRX $18.00
- Technical
- Relative Strength Index (RSI)
- ORIC 59.70
- PLRX 47.63
- Support Level
- ORIC $9.95
- PLRX $10.35
- Resistance Level
- ORIC $12.01
- PLRX $11.07
- Average True Range (ATR)
- ORIC 0.86
- PLRX 0.55
- MACD
- ORIC 0.04
- PLRX 0.11
- Stochastic Oscillator
- ORIC 64.50
- PLRX 55.75
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.